{"product_id":"lucivemu-vemurafenib","title":"LuciVemu (Vemurafenib)","description":"\u003ch2\u003eAbout Vemurafenib \u003c\/h2\u003e\u003cp\u003eVemurafenib is a medication used for the treatment of late-stage melanoma.\u003csup id=\"cite_ref-pmid20823850_2-1\" class=\"reference\"\u003e\u003c\/sup\u003e It is an inhibitor of the B-Raf enzyme.\u003c\/p\u003e\u003cdiv class=\"drugdbsectioncontent drug\"\u003e\u003cdiv id=\"content_0\"\u003e\u003cdiv class=\"refsection_content\"\u003e\u003cdiv id=\"dose_tabs_content\"\u003e\u003cdiv id=\"dose_adult\"\u003e\n\u003ch3\u003eMalignant Melanoma\u003c\/h3\u003e\n\u003cp\u003eIndicated for treatment of unresectable or metastatic melanoma with BRAF-V600E mutation as detected by an FDA-approved test\u003c\/p\u003e\n\u003cp\u003e960 mg (4 x 240 mg tablets) PO q12hr (administer approximately 12 hr apart)\u003c\/p\u003e\n\u003cp\u003eSee also Administration\u003c\/p\u003e\n\u003ch3\u003eErdheim-Chester Disease\u003c\/h3\u003e\n\u003cp\u003eIndicated for the treatment of Erdheim-Chester Disease (ECD) with BRAF V600 mutation\u003c\/p\u003e\n\u003cp\u003e960 mg (4 x 240 mg tablets) PO q12hr (administer approximately 12 hr apart)\u003c\/p\u003e\n\u003ch3\u003eOrphan Designations\u003c\/h3\u003e\n\u003cp\u003eThyroid cancer: Treatment of anaplastic thyroid carcinoma and advanced papillary thyroid cancer whose tumors harbor a BRAF V600 mutation\u003c\/p\u003e\n\u003cp\u003eNon-small cell lung cancer (NSCLC) with BRAF V600E mutation\u003c\/p\u003e\n\u003c\/div\u003e\u003c\/div\u003e\u003c\/div\u003e\u003c\/div\u003e\u003c\/div\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797954818091,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0946.jpg?v=1787022229","url":"https:\/\/xomeds.com\/products\/lucivemu-vemurafenib","provider":"XOMEDS","version":"1.0","type":"link"}